LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

LLY

1,034.59

+1.12%↑

JNJ

228.79

-0.73%↓

ABBV

212.92

+0.33%↑

UNH

382.76

-1.69%↓

AZN

187.05

+0.13%↑

Home・Lista de Ações・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Fechado

SetorSaúde

155.78 2.08

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

144.21

Máximo

156.65

Indicadores-chave
By Trading Economics
Rendimento	262M -15M
Vendas	1.6M 996M
EPS	2.06
Margem de lucro	-1.486
Funcionários	18,300
EBITDA	-11M 187M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+34.74% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-1.3B 7.2B
Abertura anterior	153.7
Fecho anterior	155.78

Sentimento de Notícias

By Acuity

22%

78%

46 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

117.16 / 144.77 Suporte e Resistência

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de mai. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 de mai. de 2026, 22:52 UTC

Grandes Movimentos do Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 de mai. de 2026, 23:44 UTC

Ganhos

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 de mai. de 2026, 23:35 UTC

Conversa de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 de mai. de 2026, 23:15 UTC

Conversa de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 de mai. de 2026, 23:14 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 de mai. de 2026, 23:02 UTC

Conversa de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 22:27 UTC

Conversa de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 de mai. de 2026, 22:14 UTC

Conversa de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 de mai. de 2026, 22:10 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 de mai. de 2026, 22:00 UTC

Ganhos

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 de mai. de 2026, 21:38 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 de mai. de 2026, 21:27 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 de mai. de 2026, 21:20 UTC

Ganhos

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 de mai. de 2026, 21:19 UTC

Ganhos

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 de mai. de 2026, 21:18 UTC

Ganhos

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 de mai. de 2026, 21:16 UTC

Ganhos

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

34.74% parte superior

Previsão para 12 meses

Média 205.38 USD 34.74%

Máximo 235 USD

Mínimo 160 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

46 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.